GO:0106217 tRNA C3-cytosine methylation Guide

tRNA C3-cytosine methylation (GO:0106217) is a biological process in which a cytosine residue within a transfer RNA (tRNA) molecule is methylated at position 3 of the cytosine base. This modification is one of many post-transcriptional chemical marks that expand the functional repertoire of RNA, collectively known as the epitranscriptome. The reaction is catalyzed by RNA (C5-cytosine) methyltransferases, a family of enzymes that transfer a methyl group from S-adenosylmethionine to the carbon-5 position of cytosine, with C3 methylation representing a distinct but related chemical modification. Because tRNAs are central to protein synthesis, chemical modifications such as C3-cytosine methylation can influence tRNA folding, stability, and decoding accuracy. Researchers study GO:0106217 to understand how epitranscriptomic marks fine-tune translation and how their loss contributes to human disease. Mitochondrial translation, for example, requires folate-dependent tRNA methylation, linking one-carbon metabolism directly to organellar protein synthesis. In cancer, methylation of tRNA at other positions (such as m7G) restricts tumorigenesis by fueling cell cycle blockade, illustrating how tRNA modifications can act as tumor suppressors. Similarly, tRNA m1A modification regulates hematopoietic stem cell maintenance and self-renewal via mTORC1 signaling, demonstrating that tRNA methylation pathways intersect with major growth-control networks. The importance of tRNA C3-cytosine methylation extends to stem cell biology and development. Mettl1/Wdr4-mediated m7G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation, establishing a precedent for how tRNA methylation governs cell fate. Post-transcriptional methylation of mitochondrial tRNA differentially contributes to mitochondrial pathology, suggesting that specific methylation events can have distinct physiological consequences. This article synthesizes the current understanding of GO:0106217, its enzymatic machinery, its regulation, and the experimental models used to study it.

tRNA C3-cytosine methylation (GO:0106217) is the process whereby a cytosine nucleotide in a tRNA molecule is methylated at position 3 of the cytosine ring. This covalent modification is introduced post-transcriptionally and is part of the broader class of RNA cytosine methylation events that regulate RNA structure and function.

tRNA C3-cytosine methylation is important because it represents a conserved layer of epitranscriptomic control over protein synthesis. Chemical modifications of tRNA, including cytosine methylation, influence how tRNAs fold, how stable they are, and how accurately they decode mRNA. Disruption of these marks can impair mitochondrial translation, which depends on folate-dependent tRNA methylation, and can contribute to mitochondrial pathology. In cancer, tRNA methylation pathways can restrict tumorigenesis by inducing cell cycle blockade, while in stem cells they are required for self-renewal and differentiation. Thus, understanding GO:0106217 provides mechanistic insight into translation control, metabolic integration, and disease.

The following genes and proteins are experimentally implicated in tRNA methylation pathways, including cytosine methylation and related modifications that inform the study of GO:0106217.

tRNA C3-cytosine methylation is regulated by the availability of S-adenosylmethionine and by one-carbon metabolism, particularly folate-dependent pathways that supply methyl groups. Signaling networks such as mTORC1 intersect with tRNA methylation pathways to control stem cell maintenance and self-renewal. Additionally, demethylases such as ALKBH1 and FTO can remove methylation marks, providing a dynamic balance between writers and erasers. The expression levels of methyltransferase enzymes themselves are also subject to regulation, as seen with METTL1 in cancer and stem cells.

Dysregulation of tRNA methylation is increasingly recognized in cancer. METTL1-mediated tRNA m7G methylation restricts breast cancer tumorigenesis by fueling cell cycle blockade, indicating that tRNA methylation can act as a tumor-suppressive mechanism. Loss of proper tRNA modification may therefore promote uncontrolled proliferation. The broader family of RNA C5-cytosine methyltransferases, which includes enzymes responsible for cytosine methylation, is implicated in cancer biology.

Post-transcriptional methylation of mitochondrial tRNA differentially contributes to mitochondrial pathology. Mitochondrial translation requires folate-dependent tRNA methylation, and defects in this process impair oxidative phosphorylation. Mutations or deficiencies in mitochondrial tRNA modification enzymes can lead to mitochondrial disease with diverse clinical presentations.

Mettl1/Wdr4-mediated m7G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation. tRNA m1A modification regulates hematopoietic stem cell maintenance and self-renewal via mTORC1 signaling. These findings suggest that disruption of tRNA methylation pathways could contribute to stem cell failure and developmental abnormalities.

Detecting C3-cytosine methylation in tRNA requires specialized methods such as mass spectrometry, which can identify and quantify modified nucleosides. tRNA sequencing approaches combined with chemical treatments can map modification sites. These methods are essential to confirm that a candidate enzyme indeed deposits the mark.

Ribosome profiling (Ribo-seq) and polysome profiling measure translation efficiency and fidelity. Because tRNA methylation affects translation, these assays can reveal functional consequences of losing or gaining the modification. Mitochondrial translation can be assessed with dedicated mitochondrial ribosome profiling.

Proteomic analysis can identify changes in protein expression resulting from altered tRNA methylation. Metabolomics can measure S-adenosylmethionine and folate pathway intermediates that supply methyl groups. Together, these approaches link tRNA modification status to cellular metabolism.

Fluorescence microscopy of tagged methyltransferases can reveal their subcellular localization, such as mitochondria or nucleus. Live-cell imaging can track tRNA dynamics and modification-dependent changes. These methods complement biochemical assays to provide spatial context.

Researchers studying tRNA C3-cytosine methylation-related genes often need to determine whether a candidate gene is causally involved in tRNA modification, translation control, or disease phenotypes. Establishing causality requires precise genetic models that can knock out, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides end-to-end CRISPR services to generate such models and to support functional genomics screens.

tRNA C3-cytosine methylation (GO:0106217) is a conserved epitranscriptomic modification that influences tRNA function, translation, and cellular metabolism. Its study bridges RNA biology, metabolism, and disease, with emerging links to cancer, mitochondrial pathology, and stem cell regulation. Continued research using precise CRISPR models and multi-omics approaches will clarify how this modification contributes to human health and disease.